166 related articles for article (PubMed ID: 37457880)
1. A Phase I Randomized Trial of Once-Daily Versus Twice-Daily Recombinant Human Parathyroid Hormone (1-84) for Hypoparathyroidism.
Ing SW; Finkelman RD; He P; Khan AA; Mannstadt M; Rejnmark L; Song I; Takács I; Wu Y
JBMR Plus; 2023 Jul; 7(7):e10758. PubMed ID: 37457880
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study.
Mannstadt M; Clarke BL; Vokes T; Brandi ML; Ranganath L; Fraser WD; Lakatos P; Bajnok L; Garceau R; Mosekilde L; Lagast H; Shoback D; Bilezikian JP
Lancet Diabetes Endocrinol; 2013 Dec; 1(4):275-83. PubMed ID: 24622413
[TBL] [Abstract][Full Text] [Related]
3. Extended Treatment With Recombinant Human Parathyroid Hormone (1-84) in Adult Patients With Chronic Hypoparathyroidism.
Rubin MR; Cusano N; Yin S; Tokareva E; Ayodele O; Finkelman RD
Endocr Pract; 2024 Mar; 30(3):200-208. PubMed ID: 38086524
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study.
Clarke BL; Kay Berg J; Fox J; Cyran JA; Lagast H
Clin Ther; 2014 May; 36(5):722-36. PubMed ID: 24802860
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human parathyroid hormone (1-84) replacement therapy in a child with hypoparathyroidism.
Laurer E; Grünberger J; Naidoo U; Lanzersdorfer R; Wimleitner M; Tischlinger K; Högler W
Bone; 2021 Mar; 144():115834. PubMed ID: 33359892
[TBL] [Abstract][Full Text] [Related]
6. AN OPEN-LABEL EXTENSION STUDY OF PARATHYROID HORMONE RHPTH(1-84) IN ADULTS WITH HYPOPARATHYROIDISM.
Lakatos P; Bajnok L; Lagast H; Valkusz Z
Endocr Pract; 2016 May; 22(5):523-32. PubMed ID: 26684150
[TBL] [Abstract][Full Text] [Related]
7. Therapy of Hypoparathyroidism With PTH(1-84): A Prospective Six Year Investigation of Efficacy and Safety.
Rubin MR; Cusano NE; Fan WW; Delgado Y; Zhang C; Costa AG; Cremers S; Dworakowski E; Bilezikian JP
J Clin Endocrinol Metab; 2016 Jul; 101(7):2742-50. PubMed ID: 27144931
[TBL] [Abstract][Full Text] [Related]
8. Open-label extension of a randomized trial investigating safety and efficacy of rhPTH(1-84) in hypoparathyroidism.
Khan AA; Abbott LG; Ahmed I; Ayodele O; Gagnon C; Finkelman RD; Mezosi E; Rejnmark L; Takacs I; Yin S; Ing SW
JBMR Plus; 2024 Mar; 8(3):ziad010. PubMed ID: 38741607
[TBL] [Abstract][Full Text] [Related]
9. Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study.
Clarke BL; Vokes TJ; Bilezikian JP; Shoback DM; Lagast H; Mannstadt M
Endocrine; 2017 Jan; 55(1):273-282. PubMed ID: 27734257
[TBL] [Abstract][Full Text] [Related]
10. Safety, tolerability, pharmacokinetics, and pharmacodynamics of recombinant human parathyroid hormone (1-34) in healthy Chinese subjects.
Liu Y; Yang C; Li Z; Zhou J; Lv Y; Zhang Y; Zeng F; Shi S
Clin Ther; 2014 Jun; 36(6):940-52. PubMed ID: 24793535
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Oral Human Parathyroid Hormone (1-34) in Hypoparathyroidism: An Open-Label Study.
Ish-Shalom S; Caraco Y; Khazen NS; Gershinsky M; Szalat A; Schwartz P; Arbit E; Galitzer H; Tang JC; Burshtein G; Rothner A; Raskin A; Blum M; Fraser WD
J Bone Miner Res; 2021 Jun; 36(6):1060-1068. PubMed ID: 33666947
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial.
Khan AA; Rubin MR; Schwarz P; Vokes T; Shoback DM; Gagnon C; Palermo A; Marcocci C; Clarke BL; Abbott LG; Hofbauer LC; Kohlmeier L; Pihl S; An X; Eng WF; Smith AR; Ukena J; Sibley CT; Shu AD; Rejnmark L
J Bone Miner Res; 2023 Jan; 38(1):14-25. PubMed ID: 36271471
[TBL] [Abstract][Full Text] [Related]
13. PTH(1-84) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment.
Sikjaer T; Amstrup AK; Rolighed L; Kjaer SG; Mosekilde L; Rejnmark L
J Bone Miner Res; 2013 Oct; 28(10):2232-43. PubMed ID: 23649554
[TBL] [Abstract][Full Text] [Related]
14. Therapy of Hypoparathyroidism With rhPTH(1-84): A Prospective, 8-Year Investigation of Efficacy and Safety.
Tay YD; Tabacco G; Cusano NE; Williams J; Omeragic B; Majeed R; Gomez Almonte M; Bilezikian JP; Rubin MR
J Clin Endocrinol Metab; 2019 Nov; 104(11):5601-5610. PubMed ID: 31310310
[TBL] [Abstract][Full Text] [Related]
15. Teriparatide (rhPTH 1-34) treatment in the pediatric age: long-term efficacy and safety data in a cohort with genetic hypoparathyroidism.
Tuli G; Buganza R; Tessaris D; Einaudi S; Matarazzo P; de Sanctis L
Endocrine; 2020 Feb; 67(2):457-465. PubMed ID: 31705387
[TBL] [Abstract][Full Text] [Related]
16. Multicenter retro-prospective observational study on chronic hypoparathyroidism and rhPTH (1-84) treatment.
Marcucci G; Beccuti G; Carosi G; Cetani F; Cianferotti L; Colao AM; Di Somma C; Duradoni M; Elefante A; Ghizzoni L; Giusti M; Lania AG; Lavezzi E; Madeo B; Mantovani G; Marcocci C; Masi L; Parri S; Pigliaru F; Santonati A; Spada A; Vera L; Brandi ML
J Endocrinol Invest; 2022 Sep; 45(9):1653-1662. PubMed ID: 35460461
[TBL] [Abstract][Full Text] [Related]
17. Drug safety evaluation of parathyroid hormone for hypocalcemia in patients with hypoparathyroidism.
Marcucci G; Della Pepa G; Brandi ML
Expert Opin Drug Saf; 2017 May; 16(5):617-625. PubMed ID: 28332412
[TBL] [Abstract][Full Text] [Related]
18. Continuous rhPTH (1-34) treatment in chronic hypoparathyroidism.
Fuss CT; Burger-Stritt S; Horn S; Koschker AC; Frey K; Meyer A; Hahner S
Endocrinol Diabetes Metab Case Rep; 2020 May; 2020():. PubMed ID: 32478671
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of oral recombinant human parathyroid hormone [rhPTH(1-31)NH₂] in postmenopausal women with osteoporosis.
Sturmer A; Mehta N; Giacchi J; Cagatay T; Tavakkol R; Mitta S; Fitzpatrick L; Wald J; Trang J; Stern W
Clin Pharmacokinet; 2013 Nov; 52(11):995-1004. PubMed ID: 23719683
[TBL] [Abstract][Full Text] [Related]
20. Transitory Activation and Improved Transition from Erosion to Formation within Intracortical Bone Remodeling in Hypoparathyroid Patients Treated with rhPTH(1-84).
van Dijk Christiansen P; Sikjær T; Andreasen CM; Thomsen JS; Brüel A; Hauge EM; Delaisse JM; Rejnmark L; Andersen TL
JBMR Plus; 2023 Dec; 7(12):e10829. PubMed ID: 38130746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
